That morning, Barclays changed its recommendation on Illumina stock to underweight (read: sell) from the previous equal weight (hold). It also pulled the lever on a significant price target decrease, ...

In early February 2026, Illumina reported past fourth-quarter 2025 revenue of US$1,159 million and net income of US$334 ...

Illumina's stock has rebounded 25% since October 2023, despite underwhelming revenue growth and challenges with the NovaSeq X platform and macro headwinds. The company faces issues with the adoption ...

On Friday, Nasdaq Inc’s (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on December 23. Illumina, Inc. (NASDAQ:ILMN) was removed from the ...

Illumina (ILMN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a ...

Genomics company Illumina (NASDAQ:ILMN) will be reporting results this Thursday after market close. Here’s what you need to ...

Shares of Illumina (ILMN) are down about 2% after the biotechnology company reported mixed third-quarter financial results. Illumina announced earnings per share (EPS) of $1.14, which was well ahead ...

Illumina Inc. (Nasdaq: ILMN), a genomics and molecular diagnostics company headquartered in San Diego, closed in late January on its acquisition of Boulder-based biotech firm SomaLogic Inc.

Illumina (ILMN) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $0.86 per share a year ago. These figures are ...

Illumina exhibits better profitability ratios than many of its peers, which indicates that the company could continue to invest in its operations. In Q3 2025, ILMN raised its EPS to $4.65-$4.75, ...